← All trials
NCT05327426
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2022
- Primary completion
- Dec 31, 2023
- Completion date
- Apr 25, 2024
- First posted
- Apr 14, 2022
- Last posted
- Sep 6, 2022
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of VermontLead sponsor
- University of VermontReponsible party - principal investigator
- World Health OrganizationCollaborator
- University of VermontSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.